Karanth Marsur Prabhakar Swathi, Ramaswamy Swapna, Basavarajachar Vanitha, Chakraborty Anushree, Shivananjiah Akshata, Chikkavenkatappa Nagaraja
Department of Pulmonary Medicine, Shanthabai Devarao Shivaram Tuberculosis Research Center and Rajiv Gandhi Institute of Chest Diseases, Bangalore, Karnataka.
The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Projects, Swami Vivekananda Youth Movement, Bangalore, Karnataka.
Thorac Res Pract. 2023 Mar;24(2):53-60. doi: 10.5152/ThoracResPract.2023.22029.
Wide arrays of laboratory parameters have been proposed by many studies for prognosis in COVID-19 patients. In this study, we wanted to determine if the International Severe Acute Respiratory and Emerging Infections Consortium-Coronavirus Clinical Characterization Consortium score in addition to certain clinical and laboratory parameters would help in predicting mortality. We wanted to determine if a greater severity score on chest x-ray at presentation translated to poor patient outcomes using the COVID-19 chest radiography score.
This retrospective study was conducted at SDS TRC and Rajiv Gandhi Institute of chest diseases, Bangalore from March 2021 to June 2021. This study included 202 real-time-polymerase chain reaction-positive COVID-19 patients aged above 18 years admitted to the intensive care unit of our hospital. Demographic characteristics and baseline hematological and inflammatory markers (serum C-reactive protein, lactate dehydrogenase, troponin-I, ferritin, and d-dimer) were collected. Radiological severity on a chest x-ray was assessed using the validated COVID-19 chest radiography score. The International Severe Acute Respiratory and Emerging Infections Consortium-Coronavirus Clinical Characterization Consortium score was assigned to each patient within 24 hours of intensive care unit admission. Outcome studied was in-hospital mortality.
The overall mortality was 54.9% (111 cases). Age more than 50 years, >4 days of symptoms, peripheral oxygen saturation/ fraction of inspired oxygen ratio less than 200, elevated serum lactate dehydrogenase >398.5 IU/L, and hypoalbuminemia (<2.95 g/dL) were detected as independent predictors of mortality. A significant correlation of risk stratification with mortality (P = .057) was seen with International Severe Acute Respiratory and Emerging Infections Consortium-Coronavirus Clinical Characterization Consortium score. There was no significant correlation between the COVID-19 chest radiography score and mortality.
Age >50 years, peripheral oxygen saturation/fraction of inspired oxygen ratio <200, mean symptom duration of >4 days, elevated serum lactate dehydrogenase, and hypoalbuminemia are independent predictors of mortality in severe COVID-19 pneumonia. International Severe Acute Respiratory and Emerging Infections Consortium-Coronavirus Clinical Characterization Consortium score was different in the survivors and deceased.
许多研究提出了大量实验室参数用于预测新冠肺炎患者的预后。在本研究中,我们想确定除某些临床和实验室参数外,国际严重急性呼吸和新发感染联盟-冠状病毒临床特征联盟评分是否有助于预测死亡率。我们还想通过新冠肺炎胸部X线评分来确定入院时胸部X线显示的严重程度评分更高是否意味着患者预后较差。
本回顾性研究于2021年3月至2021年6月在班加罗尔的SDS TRC和拉吉夫·甘地胸科疾病研究所进行。本研究纳入了202例年龄在18岁以上、因实时聚合酶链反应呈阳性而入住我院重症监护病房的新冠肺炎患者。收集了人口统计学特征以及基线血液学和炎症标志物(血清C反应蛋白、乳酸脱氢酶、肌钙蛋白I、铁蛋白和D-二聚体)。使用经过验证的新冠肺炎胸部X线评分评估胸部X线的放射学严重程度。在重症监护病房入院24小时内为每位患者分配国际严重急性呼吸和新发感染联盟-冠状病毒临床特征联盟评分。研究的结局指标是院内死亡率。
总体死亡率为54.9%(111例)。年龄超过50岁、症状持续超过4天、外周血氧饱和度/吸入氧分数比低于200、血清乳酸脱氢酶升高>398.5 IU/L以及低白蛋白血症(<2.95 g/dL)被检测为死亡率的独立预测因素。国际严重急性呼吸和新发感染联盟-冠状病毒临床特征联盟评分与死亡率存在显著的风险分层相关性(P = 0.057)。新冠肺炎胸部X线评分与死亡率之间无显著相关性。
年龄>50岁、外周血氧饱和度/吸入氧分数比<200、平均症状持续时间>4天、血清乳酸脱氢酶升高以及低白蛋白血症是重症新冠肺炎肺炎死亡率的独立预测因素。国际严重急性呼吸和新发感染联盟-冠状病毒临床特征联盟评分在幸存者和死亡者中有所不同。